Ghana Fills Critical Gap in African Clinical Cannabis Research

CED Clinical describes Ghana's Cannabis Regulatory Programme as a critical milestone for clinical cannabis research across sub-Saharan Africa — one that could generate population-specific medical data that does not currently exist globally.

The Research Gap Ghana Can Fill

Nearly all clinical data on cannabinoid-based medicines has been generated from North American and European populations. Sub-Saharan African populations have distinct genetic profiles, disease burdens, and drug metabolism patterns. Ghana's R&D licence creates the first legal pathway to study cannabinoid therapies in Ghanaian patient populations.

Target Therapeutic Areas

• Chronic pain management using CBD-based therapies
• Epilepsy and seizure disorders — CBD has the strongest clinical evidence of any cannabinoid drug
• Neuropathic pain in HIV/AIDS patients
• Chemotherapy-induced nausea and appetite loss
• Anxiety and PTSD in post-conflict populations

Read the full CED Clinical analysis